FDA Asks Healthcare Professionals to Weigh the Benefits and Risks of Topamax, Reports The CJF

FDA Asks Healthcare Professionals to Weigh the Benefits and Risks of Topamax, Reports The CJF The FDA recently released a safety announcement urging healthcare professionals to consider all benefits and risks involved in Topamax treatment before prescribing the antiepileptic drug to women of childbearing age. According to the FDA, Topamax use during pregnancy may be linked to an increased risk of birth defects among exposed infants, particularly cleft lip and cleft palate. For more information about Topamax FDA warnings and the pregnancy risks of the antiepileptic Topamax, visit http://www.
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations